A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure
MD Anderson Study Status
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Myelodysplastic Syndromes (MDS)
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.